Search

everythinglearnresearchcommunity

for

Search:↓

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The user has low testosterone and DHT levels and is considering taking finasteride for Norwood 2 hair loss with diffuse thinning. They are seeking advice on whether low DHT indicates high sensitivity to DHT in the scalp and opinions on their lab values.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user inquires if RENU Biogen is a DHT inhibitor.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.

User wants to add RCP to regimen and asks if it can be applied with topical minoxidil and/or finasteride at night.

A 35-year-old MTF individual shared their hair recovery journey, using Minoxidil, Dutasteride, Estradiol, Spironolactone, Microneedling, and Exosomes. They recently had a hair transplant and are documenting the healing process.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The user switched from finasteride and topical minoxidil to dutasteride, oral minoxidil, and topical minoxidil for 8 months, resulting in hair regrowth. Some users suggest dropping the topical minoxidil.

Current hair loss treatments include finasteride, dutasteride, minoxidil, and derma rolling. New treatments like TDM-105795, GT20029, and others show promise but require more testing and time before approval.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

The conversation is about users trying to regain access to a Discord server related to pp405 research, with differing opinions on the effectiveness of pp405 for hair loss. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned in the conversation.

Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.

The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

Testosterone within the normal range does not significantly contribute to male pattern baldness (MPB); DHT is the main factor that can be controlled. Genetics play a crucial role in hair loss, and treatments like finasteride and dutasteride, which block DHT, can help despite potentially raising testosterone levels.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The user shared their 5-year hair loss journey, initially using a product called Triphasic Progressive by Rene Furterer, which gave good results. Later, they switched to FDA-approved medications finasteride and minoxidil, which also helped, but they noticed the most significant progress with Triphasic. They're considering trying it again if minoxidil doesn't show improvements.

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

Before getting a hair transplant, it's crucial to research and understand that ongoing treatments like finasteride, dutasteride, or minoxidil are necessary to maintain results. Concerns were raised about Turkish clinics, including overharvesting grafts, lack of regulations, and discouraging finasteride use.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

Trans woman experiencing thinning hair despite low testosterone and finasteride use seeks possible causes and solutions. Current treatments include finasteride, spironolactone, estradiol, vitamins, and microneedling; minoxidil not tried due to concerns about dependence and side effects.

A man lost his transplanted hair despite using minoxidil because he wasn't on a DHT blocker like finasteride, which is essential to prevent further hair loss. The conversation emphasizes that hair transplants are not a cure and require maintenance with medications to preserve results.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

The user switched from finasteride to dutasteride for hair loss and saw significant improvement in under two months. They also microneedle, take supplements including collagen and vitamin D3, use ketoconazole shampoo, and noticed accidental hair regrowth with retinol application on their face.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.